SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy Article

publication date

  • April 15, 2019

webpage

volume

  • 3

issue

  • Suppl